Trastuzumab deruxtecan is a HER-2 directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of metastatic, unresectable breast cancer. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class. Trastuz...
In the US, trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. It...
City of Hope Comprehensive Cancer Center, Duarte, California, United States
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
City of Hope at Irvine Lennar, Irvine, California, United States
Research Site, Zhengzhou City, China
Research Site, Khon Kaen, Thailand
Massachusetts General Hospital, Boston, Massachusetts, United States
Research Site, Çankaya, Turkey
Research Site, Zhengzhou, China
Brigham and Women's Hospital, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Research Site, Taunton, United Kingdom
AKH Universitaetsklinikum Vienna, Department f. Internal medicine I, oncology, Vienna, Austria
Research Site, Edinburgh, United Kingdom
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.